{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:16:37Z","timestamp":1793506597559,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017239","name":"BeiGene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.radonc.2025.110797","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:06:03Z","timestamp":1739905563000},"page":"110797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Neoadjuvant chemoradiotherapy plus sequential tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): A single-arm, bicentric, phase 2 trial"],"prefix":"10.1016","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6318-2524","authenticated-orcid":false,"given":"Jinsong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jielin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangqin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buhai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110797_b0005","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.110797_b0010","first-page":"2796","article-title":"Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized,","volume":"36","author":"Yang","year":"2018","journal-title":"Open-Label Clinical Trial. J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0015","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0020","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","article-title":"Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.radonc.2025.110797_b0025","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1002\/cncr.21439","article-title":"Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response","volume":"104","author":"Rohatgi","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.110797_b0030","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1200\/JCO.2005.05.017","article-title":"Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival","volume":"23","author":"Berger","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0035","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10434-999-0777-x","article-title":"Induction chemo-radiotherapy for squamous cell carcinoma of the thoracic esophagus: long-term results of a phase II study","volume":"6","author":"Laterza","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0040","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/annonc\/mdh219","article-title":"A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma","volume":"15","author":"Lee","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0045","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijrobp.2007.10.009","article-title":"Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy","volume":"71","author":"Kim","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110797_b0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial","volume":"34","author":"Tang","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0055","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.21.01926","article-title":"Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study","volume":"40","author":"Shen","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0065","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.110797_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102118","article-title":"A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)","volume":"62","author":"Chen","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.radonc.2025.110797_b0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008229","article-title":"Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial","volume":"12","author":"Jiang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.radonc.2025.110797_b0080","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ijrobp.2023.12.033","article-title":"A Phase 1b Clinical Trial of Neoadjuvant Radio-immunotherapy for Esophageal Squamous Cell Cancer","volume":"119","author":"Li","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110797_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008631","article-title":"Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer","volume":"12","author":"Xu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.radonc.2025.110797_b0090","doi-asserted-by":"crossref","unstructured":"Zhang Y, Yuan Y, Xu Y, Tian R, Liao J, Zeng X, et al. 1540P Tislelizumab combined with neoadjuvant chemoradiotherapy for resectable locally advanced oesophageal squamous cell carcinoma: A prospective, phase II clinical study. ESMO Congress 2023. Annals of Oncology. 2023;34:Supplement 2. DOI: 10.1016\/j.annonc.2023.09.1452.","DOI":"10.1016\/j.annonc.2023.09.1452"},{"key":"10.1016\/j.radonc.2025.110797_b0095","doi-asserted-by":"crossref","unstructured":"He W, Wang C, Wu L, Wan G, Han Y, Leng X, et al. 1529P Tislelizumab plus chemotherapy sequential neo-chemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT). ESMO Congress 2023. Annals of Oncology. 2023;34:Supplement 2. DOI: 10.1016\/j.annonc.2023.09.1441.","DOI":"10.1016\/j.annonc.2023.09.1441"},{"key":"10.1016\/j.radonc.2025.110797_b0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4070","article-title":"Safety and feasibility of esophagectomy following neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: Analysis of two phase 2 clinical trials. 2024 ASCO Annual Meeting","volume":"42","author":"Shen","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e16116","article-title":"Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a single-arm, open-label phase Ib trial (CRIS). 2024 ASCO Annual Meeting","volume":"42","author":"Jiang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e16098","article-title":"Neoadjuvant nivolumab plus paclitaxel\/cisplatin- chemo-radiotherapy (neo-NTP-CRT) followed by esophagectomy for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II study. 2024 ASCO Annual Meeting","volume":"42","author":"Huang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0115","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.110797_b0120","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/annonc\/mdy291","article-title":"Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. 2018 ESMO Congress","volume":"29","author":"Faivre-Finn","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12885-023-10687-8","article-title":"Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2025.110797_b0135","doi-asserted-by":"crossref","unstructured":"Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer. J Thorac Oncol. 2017;12:36-42. DOI: 10.1016\/j.jtho.2016.10.016.","DOI":"10.1016\/j.jtho.2016.10.016"},{"key":"10.1016\/j.radonc.2025.110797_b0140","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/cncr.20916","article-title":"Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation","volume":"103","author":"Chirieac","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.110797_b0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.0133","article-title":"Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial","author":"Wang","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.radonc.2025.110797_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.2112","article-title":"LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial. ESMO Congress 2021","volume":"32","author":"Bourhis","year":"2021","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.radonc.2025.110797_b0155","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0160","doi-asserted-by":"crossref","unstructured":"Bradley JD, Sugawara S, Lee KHH, Ostoros G, Demirkazik A, Zemanova M, et al. LBA1 - Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2. European Lung Cancer Congress 2024. ESMO Open. 2024;9:suppl_3. DOI: 10.1016\/j.esmoop.2024.102986.","DOI":"10.1016\/j.esmoop.2024.102986"},{"key":"10.1016\/j.radonc.2025.110797_b0165","first-page":"S2","article-title":"856MO A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and tumor-immune microenvironment analysis","volume":"34","author":"Zandberg","year":"2023","journal-title":"ESMO Congress 2023. Annals of Oncology."},{"key":"10.1016\/j.radonc.2025.110797_b0170","doi-asserted-by":"crossref","unstructured":"Eads JR, Graham N, Gibson MK, Rajdev L, Chakravarthy AB, Khullar OV, et al. A phase II\/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174). 2024 ASCO Annual Meeting. Journal of Clinical Oncology. 2024;42:16_suppl. DOI: 10.1200\/JCO.2024.42.16_suppl.4000.","DOI":"10.1200\/JCO.2024.42.16_suppl.4000"},{"key":"10.1016\/j.radonc.2025.110797_b0175","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0180","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jamaoncol.2021.6439","article-title":"Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US food and drug administration database","volume":"8","author":"Anscher","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0185","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(23)00060-8","article-title":"Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial","volume":"24","author":"Zhu","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30617-X","article-title":"Oesophageal preservation in locally advanced oesophageal cancer","volume":"19","author":"Ajani","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0195","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2014.11.010","article-title":"A qualitative synthesis of the evidence behind elective lymph node irradiation in oesophageal cancer","volume":"113","author":"Van De Voorde","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0200","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.canlet.2014.11.045","article-title":"Involved field irradiation for the treatment of esophageal cancer: is it better than elective nodal irradiation?","volume":"357","author":"Jiang","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.radonc.2025.110797_b0205","unstructured":"NCCN Guidelines: Esophageal and Esophagogastric Junction Cancers (Version 3.2024). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1433. [Accessed May 18, 2024]."},{"key":"10.1016\/j.radonc.2025.110797_b0210","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.ijrobp.2015.03.030","article-title":"Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer","volume":"92","author":"Wu","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110797_b0215","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.radonc.2020.11.032","article-title":"Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer","volume":"156","author":"Thomas","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0220","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijrobp.2017.05.037","article-title":"Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy","volume":"99","author":"Davuluri","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110797_b0225","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.110797_b0230","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(19)30171-8","article-title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy","volume":"20","author":"Deutsch","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110797_b0235","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2020.08.002","article-title":"Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010","volume":"138","author":"Liu","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.110797_b0240","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/SLA.0000000000002670","article-title":"Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes","volume":"269","author":"Xi","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2025.110797_b0245","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrab022","article-title":"Pattern of recurrence in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer","volume":"5","author":"de Jongh","year":"2021","journal-title":"BJS Open"},{"key":"10.1016\/j.radonc.2025.110797_b0250","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1245\/s10434-020-09219-6","article-title":"Pretreatment Primary Tumor Stage is a Risk Factor for Recurrence in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response After Neoadjuvant Chemoradiotherapy","volume":"28","author":"La Mendola","year":"2021","journal-title":"Ann Surg Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025000921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025000921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:44:17Z","timestamp":1777553057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":50,"alternative-id":["S0167814025000921"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110797","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant chemoradiotherapy plus sequential tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): A single-arm, bicentric, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110797","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110797"}}